Visionary Holdings: Deeply Responding to the Concerns of the Capital Market and Demonstrating Solid Development Strength
Visionary Holdings (NASDAQ: GV) has issued a comprehensive response to address capital market concerns and highlight its development trajectory. The company, focused on precision medicine and biomedical innovation, reports that its R&D expenditure maintains at 15% of total expenditure, primarily directed towards early cancer screening research.
The company's financial structure remains stable, supported by cash reserves, institutional credit, and strategic investments. Their key developments include home detection technologies for cervical and colorectal cancer, currently in clinical trials with expected market launch within 18 months. These tests offer 15-minute results and focus on detecting precancerous lesions at lower costs.
GV plans to implement a dual B2B and B2C commercialization strategy, partnering with healthcare facilities while offering direct-to-consumer sales through online channels. Future expansion will be funded through diverse financing channels, including strategic investment and bond financing, with careful consideration to minimize shareholder dilution.
Visionary Holdings (NASDAQ: GV) ha emesso una risposta completa per affrontare le preoccupazioni del mercato dei capitali e mettere in evidenza la sua traiettoria di sviluppo. L'azienda, focalizzata sulla medicina di precisione e sull'innovazione biomedica, riporta che la spesa per R&S rimane al 15% della spesa totale, principalmente diretta alla ricerca per lo screening precoce del cancro.
La struttura finanziaria dell'azienda rimane stabile, supportata da riserve di liquidità, credito istituzionale e investimenti strategici. I loro sviluppi chiave includono tecnologie di rilevamento a domicilio per il cancro cervicale e colorettale, attualmente in fase di sperimentazione clinica con un lancio previsto sul mercato entro 18 mesi. Questi test offrono risultati in 15 minuti e si concentrano sulla rilevazione di lesioni precancrose a costi inferiori.
GV prevede di implementare una strategia di commercializzazione duale B2B e B2C, collaborando con strutture sanitarie e offrendo vendite dirette al consumatore attraverso canali online. L'espansione futura sarà finanziata attraverso diversi canali di finanziamento, inclusi investimenti strategici e finanziamenti obbligazionari, con particolare attenzione a minimizzare la diluizione per gli azionisti.
Visionary Holdings (NASDAQ: GV) ha emitido una respuesta integral para abordar las preocupaciones del mercado de capitales y destacar su trayectoria de desarrollo. La empresa, centrada en la medicina de precisión y la innovación biomédica, informa que su gasto en I+D se mantiene en el 15% del gasto total, dirigido principalmente a la investigación sobre el cribado temprano del cáncer.
La estructura financiera de la empresa se mantiene estable, respaldada por reservas de efectivo, crédito institucional e inversiones estratégicas. Sus desarrollos clave incluyen tecnologías de detección en casa para el cáncer cervical y colorrectal, que actualmente se encuentran en ensayos clínicos con un lanzamiento al mercado previsto en 18 meses. Estas pruebas ofrecen resultados en 15 minutos y se centran en detectar lesiones precoces a un costo más bajo.
GV planea implementar una estrategia de comercialización dual B2B y B2C, asociándose con instalaciones de atención médica mientras ofrece ventas directas al consumidor a través de canales en línea. La expansión futura se financiará a través de diversos canales de financiamiento, incluyendo inversiones estratégicas y financiamiento de bonos, con un cuidadoso enfoque para minimizar la dilución de los accionistas.
비전홀딩스 (NASDAQ: GV)는 자본 시장의 우려를 해소하고 개발 궤적을 강조하기 위해 포괄적인 응답을 발표했습니다. 정밀 의학과 생물 의학 혁신에 중점을 둔 이 회사는 연구개발(R&D) 지출이 총 지출의 15%를 유지하고 있다고 보고하며, 주로 조기 암 검진 연구에 집중하고 있습니다.
회사의 재무 구조는 현금 보유, 기관 신용 및 전략적 투자의 지원을 받아 안정적으로 유지되고 있습니다. 주요 개발 사항으로는 자궁경부암 및 대장암에 대한 자택 탐지 기술이 있으며, 현재 임상 시험 중이며 18개월 이내에 시장 출시가 예상됩니다. 이 테스트는 15분 내에 결과를 제공하며, 저렴한 비용으로 전암 병변을 탐지하는 데 중점을 두고 있습니다.
GV는 의료 시설과 협력하여 B2B 및 B2C 상업화 전략을 구현할 계획이며, 온라인 채널을 통해 소비자에게 직접 판매를 제공합니다. 향후 확장은 전략적 투자 및 채권 자금을 포함한 다양한 자금 조달 경로를 통해 자금을 조달할 예정이며, 주주 희석을 최소화하기 위한 신중한 고려가 필요합니다.
Visionary Holdings (NASDAQ: GV) a publié une réponse complète pour aborder les préoccupations du marché des capitaux et mettre en avant sa trajectoire de développement. L'entreprise, axée sur la médecine de précision et l'innovation biomédicale, indique que les dépenses en R&D restent à 15 % des dépenses totales, principalement dirigées vers la recherche sur le dépistage précoce du cancer.
La structure financière de l'entreprise reste stable, soutenue par des réserves de liquidités, un crédit institutionnel et des investissements stratégiques. Parmi leurs développements clés figurent des technologies de détection à domicile pour le cancer du col de l'utérus et le cancer colorectal, actuellement en essais cliniques avec un lancement sur le marché prévu dans 18 mois. Ces tests offrent des résultats en 15 minutes et se concentrent sur la détection de lésions précancéreuses à moindre coût.
GV prévoit de mettre en œuvre une stratégie de commercialisation duale B2B et B2C, en s'associant à des établissements de santé tout en proposant des ventes directes aux consommateurs via des canaux en ligne. L'expansion future sera financée par divers canaux de financement, y compris des investissements stratégiques et un financement obligataire, en veillant à minimiser la dilution des actionnaires.
Visionary Holdings (NASDAQ: GV) hat eine umfassende Antwort veröffentlicht, um die Bedenken der Kapitalmärkte zu adressieren und seinen Entwicklungspfad hervorzuheben. Das Unternehmen, das sich auf präzise Medizin und biomedizinische Innovation konzentriert, berichtet, dass die F&E-Ausgaben bei 15 % der Gesamtausgaben bleiben, die hauptsächlich auf die Forschung zur frühzeitigen Krebsdiagnose gerichtet sind.
Die finanzielle Struktur des Unternehmens bleibt stabil, unterstützt durch Barreserven, institutionellen Kredit und strategische Investitionen. Zu den wichtigsten Entwicklungen gehören Heimdiagnosetechnologien für Gebärmutterhals- und Dickdarmkrebs, die sich derzeit in klinischen Studien befinden und innerhalb von 18 Monaten auf den Markt kommen sollen. Diese Tests bieten Ergebnisse in 15 Minuten und konzentrieren sich darauf, präkanzeröse Läsionen zu niedrigeren Kosten zu erkennen.
GV plant die Umsetzung einer dualen B2B- und B2C-Kommerzialisierungsstrategie, indem es Partnerschaften mit Gesundheitseinrichtungen eingeht und gleichzeitig Direktvertrieb über Online-Kanäle anbietet. Die zukünftige Expansion wird über verschiedene Finanzierungsquellen, einschließlich strategischer Investitionen und Anleihefinanzierung, finanziert, wobei sorgfältig darauf geachtet wird, die Verwässerung der Aktionäre zu minimieren.
- Clinical trials ongoing for innovative home cancer detection technologies
- R&D investment maintained at 15% of total expenditure
- Stable financial structure with multiple funding sources
- Increasing marginal profit through cost optimization
- Market launch of cancer detection products expected within 18 months
- Revenue has not reached explosive growth stage
- Faces intense market competition
- Potential future equity financing may dilute shareholders
The company has always adhered to the mission of "Innovative Medical Technology, Protecting Human Health" and has the vision of becoming a "Global Leader in Precision Medicine." Driven by this mission and vision, the company has been continuously exploring and making proactive efforts in the field of biomedicine, striving to bring more efficient and precise medical solutions to patients around the world.
In terms of finance, the company's current revenue mainly comes from the transformation of phased achievements of existing businesses. Although the current revenue scale has not yet reached the explosive growth stage, with the gradual commercialization of core products, there is a strong expectation for revenue growth. The R&D expenditure has maintained a reasonable and necessary investment level over the past few years, accounting for approximately
Facing fierce market competition, Visionary Holdings has unique competitiveness in innovation ability and R&D speed. The company focuses on breakthroughs in cutting-edge technologies in niche areas, with early cancer screening and targeted detection as its core, and adopts a differentiated competition strategy. For example, in the field of home cancer detection technology, the company's developed rapid home detection technologies for cervical cancer and colorectal cancer have entered the clinical trial stage and are expected to be officially launched on the market within 18 months. The commercialization model will adopt a combination of B2B and B2C. It will not only establish cooperation with hospitals, clinics, and pharmacies but also directly sell to consumers through online channels. The company's detection technology focuses on detecting precancerous lesions. It is fast and convenient, allowing self-testing at home, and the results can be obtained within 15 minutes. With a lower detection cost, it has stronger market competitiveness.
In terms of the profit model, in addition to the above-mentioned commercialization path of cancer screening technology, the company will also expand its profit channels through means such as technology licensing and joint development. For future expansion plans, the company's funds mainly come from diversified financing channels, including strategic investment, bond financing, etc. While ensuring the capital demand, it will carefully plan equity financing to minimize the dilution impact on existing shareholders.
Visionary Holdings has always adhered to the development concept of rigor and innovation. Under the guidance of the mission of "Innovative Medical Technology, Protecting Human Health," it is striding forward towards the vision of becoming a "Global Leader in Precision Medicine." The company is confident that with its solid technical strength, reasonable financial planning, and clear market strategy, it will achieve greater success in both the capital market and the medical field, create long-term value for shareholders, and contribute to the development of the global medical cause.
View original content:https://www.prnewswire.com/news-releases/visionary-holdings-deeply-responding-to-the-concerns-of-the-capital-market-and-demonstrating-solid-development-strength-302385119.html
SOURCE Visionary Holdings Inc.
FAQ
When will Visionary Holdings (GV) launch its home cancer detection technologies?
What percentage of expenditure does GV allocate to R&D?
How does GV's home cancer detection technology work?
What is GV's commercialization strategy for its cancer detection products?
How does Visionary Holdings (GV) plan to fund its future expansion?
